Host: |
Goat |
Applications: |
Pep-ELISA/WB/IHC |
Reactivity: |
Human/Mouse/Rat/Dog |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Goat polyclonal antibody anti-EBAG9/RCAS1 (C-Term) is suitable for use in ELISA, Western Blot and Immunohistochemistry research applications. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. NA |
Purification: |
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. |
Concentration: |
0.5 mg/mL |
Dilution Range: |
WB-1-3µg/mlIHC-3.75µg/mlELISA-antibody detection limit dilution 1:64000. |
Storage Instruction: |
Store at-20°C on receipt and minimise freeze-thaw cycles. |
Gene Symbol: |
EBAG9 |
Gene ID: |
9166 |
Uniprot ID: |
RCAS1_HUMAN |
Immunogen Region: |
C-Term |
Accession Number: |
NP_004206.1 |
Immunogen Sequence: |
KEAQRLMKKEQN |
Function | May participate in suppression of cell proliferation and induces apoptotic cell death through activation of interleukin-1-beta converting enzyme (ICE)-like proteases. |
Protein Name | Receptor-Binding Cancer Antigen Expressed On Siso CellsCancer-Associated Surface Antigen Rcas1Estrogen Receptor-Binding Fragment-Associated Gene 9 Protein |
Database Links | Reactome: R-HSA-9018519 |
Cellular Localisation | Golgi Apparatus MembraneSingle-Pass Type Iii Membrane ProteinIt Also Exists As A Soluble Form Which Has The Same Biological ActivitiesThe Existence Of Such Soluble Form Is However Uncertain |
Alternative Antibody Names | Anti-Receptor-Binding Cancer Antigen Expressed On Siso Cells antibodyAnti-Cancer-Associated Surface Antigen Rcas1 antibodyAnti-Estrogen Receptor-Binding Fragment-Associated Gene 9 Protein antibodyAnti-EBAG9 antibodyAnti-RCAS1 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance